Magos A L, Brewster E, Singh R, O'Dowd T, Brincat M, Studd J W
Br J Obstet Gynaecol. 1986 Dec;93(12):1290-6. doi: 10.1111/j.1471-0528.1986.tb07868.x.
The influence of norethisterone on mood and behaviour was investigated in prospective placebo-controlled study in 58 postmenopausal hysterectomized women who were being treated with subcutaneous oestradiol and testosterone implants. Norethisterone, 2.5 or 5 mg daily, was given for 7 days and a placebo for two periods of 7 days. Psychological, behavioural and physical variables were assessed using the Menstrual Distress Questionnaire. There were widespread adverse effects which were dose-related. Significant changes in five of the eight symptom complexes studied (pain, concentration, behavioural change, water retention and negative affect) were found with 5 mg/day of the progestogen. The symptoms were similar to the typical complaints of the premenstrual syndrome, such that a combination of oestradiol and testosterone implants with cyclical oral norethisterone appears to be a model for this condition. The dose of this progestogen should therefore be the minimum to achieve the desired therapeutic effect.
在一项前瞻性安慰剂对照研究中，对58名接受皮下雌二醇和睾酮植入物治疗的绝经后子宫切除妇女，研究了炔诺酮对情绪和行为的影响。每天给予2.5毫克或5毫克炔诺酮，持续7天，并给予两个为期7天的安慰剂疗程。使用月经困扰问卷评估心理、行为和身体变量。存在广泛的不良反应，且与剂量相关。发现每天5毫克的孕激素会使所研究的八个症状复合体中的五个（疼痛、注意力、行为改变、水潴留和负面影响）发生显著变化。这些症状与经前综合征的典型主诉相似，因此，皮下雌二醇和睾酮植入物与周期性口服炔诺酮的联合应用似乎是这种病症的一个模型。因此，这种孕激素的剂量应是达到所需治疗效果的最小剂量。
